Cargando…
How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective
In Europe, trans-arterial chemoembolization (TACE) is usually given to patients with Barcelona Clinic Liver Cancer (BCLC) “intermediate stage” hepatocellular carcinoma (HCC), and is associated with a modest improvement in median overall survival. In the two positive randomized trials that have been...
Autores principales: | Raoul, Jean-Luc, Gilabert, Marine, Piana, Gilles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057788/ https://www.ncbi.nlm.nih.gov/pubmed/24945002 http://dx.doi.org/10.1159/000343867 |
Ejemplares similares
-
Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition
por: Zhang, Shen, et al.
Publicado: (2022) -
Ultraselective conventional transarterial chemoembolization: When and how?
por: Miyayama, Shiro
Publicado: (2019) -
Subsequent Treatment after Transarterial Chemoembolization Failure/Refractoriness: A Review Based on Published Evidence
por: Zhang, Shen, et al.
Publicado: (2022) -
Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?
por: Kotsifa, Evgenia, et al.
Publicado: (2022) -
Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma
por: Choi, Jonggi, et al.
Publicado: (2020)